Christian Schwager
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Christian Schwager has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Anca-Ligia Grosu
Department of Radiation Oncology, Medical Center - University of Freiburg
93 shared publications - Annett Linge
Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany
93 shared publications - Bouchra Tawk
German Cancer Research Center (DKFZ), Heidelberg, Germany and German Cancer Consortium (DKTK), Core Center Heidelberg, Germany
93 shared publications - Ina Kurth
German Cancer Research Center (DKFZ), Germany and German Cancer Consortium (DKTK), Core Center Heidelberg, Germany; Division of Radiooncology and Radiobiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
93 shared publications - Ingeborg Tinhofer
German Cancer Consortium (DKTK) Partner Site Berlin and German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany
93 shared publications - Jakob Liermann
Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany
93 shared publications
Latest Publications
- Open Access
- 9 February 2026
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 217, 111433
A tumor DNA-Methylome derived signature of Hypoxia Identifies HPV-negative head and neck cancer patients at risk for distant metastasis after postoperative radiochemotherapy (PORT-C)
- 9 February 2026
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 217, 111433
Open AccessA tumor DNA-Methylome derived signature of Hypoxia Identifies HPV-negative head and neck cancer patients at risk for distant metastasis after postoperative radiochemotherapy (PORT-C)
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy
Supplementary Table S1. Multivariate Analysis for the Hypoxia-M and Brooks signature.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy
Supplementary Table S1. Multivariate Analysis for the Hypoxia-M and Brooks signature.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy
Supplementary Figure S3. (Top) Hypoxia-M V2 is associated with decreased OS in the TCGApancancer cohort (p<0.002) (Bottom) Hypoxia-M V2 is an independent prognosticator of OS (HR=1.81, p<0.03) after adjusting for demographic and clinical factors.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy
Supplementary Figure S3. (Top) Hypoxia-M V2 is associated with decreased OS in the TCGApancancer cohort (p<0.002) (Bottom) Hypoxia-M V2 is an independent prognosticator of OS (HR=1.81, p<0.03) after adjusting for demographic and clinical factors.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy
Supplementary Table S4. Correlations with CIBERSORT immune signature expressions in the TCGA-HNSCC cohort
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy
Supplementary Table S4. Correlations with CIBERSORT immune signature expressions in the TCGA-HNSCC cohort
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy
Supplementary Table S6. Contingency Table of Hypoxia-M and CD8-immunohistochemistry (IHC) staining for CD8-T cells
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy
Supplementary Table S6. Contingency Table of Hypoxia-M and CD8-immunohistochemistry (IHC) staining for CD8-T cells
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S2 from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy
Supplementary Figure S2. (Top) Hypoxia-M V2 is prognostic in the DKTK-ROG cohort. Patients predicted to have higher tumor hypoxia by Hypoxia-M V2 had higher rates of death (p=0.0097), local recurrence (p=0.0037), distant metastasis (p=0.027) and disease progression (p=0.00096). (Bottom) Hypoxia-M V2 remains an independent prognosticator of OS, LR and disease progression after adjusting for age, smoking status, GTV and anatomical site. Additionally, there is a trend towards higher rates of distant metastasis (HR=2.33, p=0.13)
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S2 from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy
Supplementary Figure S2. (Top) Hypoxia-M V2 is prognostic in the DKTK-ROG cohort. Patients predicted to have higher tumor hypoxia by Hypoxia-M V2 had higher rates of death (p=0.0097), local recurrence (p=0.0037), distant metastasis (p=0.027) and disease progression (p=0.00096). (Bottom) Hypoxia-M V2 remains an independent prognosticator of OS, LR and disease progression after adjusting for age, smoking status, GTV and anatomical site. Additionally, there is a trend towards higher rates of distant metastasis (HR=2.33, p=0.13)
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Methods S1 from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy
Supplementary Methods, Results, Table of Contents
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods S1 from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy
Supplementary Methods, Results, Table of Contents
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy
Supplementary Table S5. Distribution of clinical and biomarker-related characteristics between Methylation Hypoxia High vs Low in the validation cohort (DKTK-ROG)
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy
Supplementary Table S5. Distribution of clinical and biomarker-related characteristics between Methylation Hypoxia High vs Low in the validation cohort (DKTK-ROG)
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy
Supplementary Figure 4 (Top). CD8 T cell enrichment is prognostic for Overall Survival (OS), local recurrence (LR) and disease progression but not for distant metastasis (DM) in HPV negative HNSCC in the DKTK-ROG cohort (n=88). (Bottom) After adjusting for Immune cell Infiltration, Hypoxia-M remained an independent prognosticator for local recurrence (HR=3.06, p<0.01) and for disease progression (HR=2.14, p<0.04) with a trend towards worsened OS (HR=1.92, p<0.09). CD8-IHC staining was an independent prognosticator for local recurrence (HR=0.41, p<0.03) an
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy
Supplementary Figure 4 (Top). CD8 T cell enrichment is prognostic for Overall Survival (OS), local recurrence (LR) and disease progression but not for distant metastasis (DM) in HPV negative HNSCC in the DKTK-ROG cohort (n=88). (Bottom) After adjusting for Immune cell Infiltration, Hypoxia-M remained an independent prognosticator for local recurrence (HR=3.06, p<0.01) and for disease progression (HR=2.14, p<0.04) with a trend towards worsened OS (HR=1.92, p<0.09). CD8-IHC staining was an independent prognosticator for local recurrence (HR=0.41, p<0.03) an